Bisphenol-A (BPA) is a component of polycarbonate and other plastics to which humans are regularly exposed at low levels. BPA is characterized as an endocrine disruptor because of observations of its estrogenic activity in various experimental models. We have previously shown evidence of disrupted hypothalamic feeding circuitry and leptin sensitivity in adult BPA-exposed animals subjected to a high-fat diet, but because these animals were already exhibiting a diet-induced obese phenotype, we could not rule out the possibility that these observations were simply consequences of the obesity, not a preexisting phenotype produced by BPA exposure. Here, we studied leptin sensitivity and hypothalamic structure in young BPA-exposed animals before the onset of a body weight or metabolic phenotype. Pregnant and lactating CD-1 mice were exposed to either BPA or diethylstilbestrol (DES) at low, environmentally relevant doses via their diet. Studies of leptin function and neurobiology were conducted on offspring at several time points. Young adult offspring from this experiment were resistant to leptin-induced suppression of food intake, body weight loss, and hypothalamic pro-opiomelanocortin (POMC) upregulation. Both male and female BPA-exposed mice showed a reduced density of POMC projections into the paraventricular nucleus of the hypothalamus (PVN). BPA-and DES-exposed pups had respectively delayed and blunted postnatal leptin surges, and POMC projections into the PVN were rescued in female BPA-exposed animals given daily injections of supplemental leptin. Our findings suggest that BPA, a putative obesogen, may exert its effects through developmental programming of the hypothalamic melanocortin circuitry, permanently altering the neurobiology of metabolic homeostasis. (Endocrinology 158: 768-777, 2017) B isphenol-A (BPA) is a compound used extensively in the production of polycarbonate plastics, epoxy resins, food containers, thermal paper, and dental sealants (1, 2). BPA can leach from these products, leading to low-dose human exposure (1). Population studies have found detectable levels of BPA and its conjugates in the urine of .90% of subjects tested, with an estimated average daily exposure of 1 to 5 mg/kg/d, making BPA exposure nearly ubiquitous (2).
B
isphenol-A (BPA) is a compound used extensively in the production of polycarbonate plastics, epoxy resins, food containers, thermal paper, and dental sealants (1, 2) . BPA can leach from these products, leading to low-dose human exposure (1) . Population studies have found detectable levels of BPA and its conjugates in the urine of .90% of subjects tested, with an estimated average daily exposure of 1 to 5 mg/kg/d, making BPA exposure nearly ubiquitous (2) .
Because BPA is an endocrine-disrupting compound with effects on a variety of systems at very low doses (2) ; widespread exposure is a public health concern. BPA is a weak agonist of the classical nuclear estrogen receptors (3, 4) and a relatively stronger agonist of the estrogensensitive membrane receptor GPR30 (5, 6) . BPA is also active at other nuclear receptors, behaving agonistically (7, 8) or antagonistically (9) at the androgen receptor, as a peroxisome proliferator-activated receptor-g agonist (10) , and as a glucocorticoid receptor agonist (11) .
Studies have shown that early-life BPA exposure can affect body weight, glucose homeostasis, and liver function in rodents (12) (13) (14) (15) . These effects are dose dependent, as shown by Wei et al. (15) , who found obesogenic effects only in rats exposed to 50 mg/kg/d BPA, equivalent to the US Environmental Protection Agency oral reference dose. Similarly, both Ryan et al. (16) and our group found no lasting metabolic defects in CD-1 mice exposed to BPA in the diet at 0.001 ppm, but we did find a number of effects with a higher dose of 0.02 ppm (13) . However, body-weight effects are not universally reported at these doses (17) , and it remains to be determined whether certain aspects of the exposure model and postnatal conditions mediate the metabolic outcome.
The pro-opiomelanocortin (POMC) and neuropeptide Y/Agouti-related peptide neurons in the arcuate nucleus (ARC) are key first-order sensors of circulating signals of energy balance such as leptin and ghrelin (18) . These neurons, and their projections to downstream effector nuclei such as the paraventricular nucleus of the hypothalamus (PVN) make up the melanocortin system. This system is programmable by developmental conditions. Indeed, leptin itself plays an important role in this process, regulating DNA methylation of the Pomc gene (19) , and acting as a neurotrophic factor that promotes the innervation of the PVN and other targets by ARC neurons (20) . Neonatal rodents exhibit a surge in circulating leptin centered on postnatal day (P) 8 that is attenuated by maternal food restriction (21) and exaggerated by maternal obesity (22) . These conditions both lead to long-term structural and functional deficits in the melanocortin circuitry. There are sex differences in the melanocortin system; in females, these can be masculinized by neonatal exposure to testosterone or 17b-estradiol (23) .
Previously, we showed that female offspring of dams orally exposed to BPA at 0.02 ppm were hyperphagic and obesity-prone on a high-fat diet, whereas males exhibited a glucose intolerant phenotype (13) . Adult males showed reductions in POMC-immunopositive fiber density in the PVN, whereas high-fat diet-exposed females, despite being hyperleptinemic, showed no upregulation of Pomc mRNA in the ARC (13) . Thus, we hypothesized that BPA exposure led to programmed central leptin resistance. Here, we demonstrate that young male and female mice exhibit programmed leptin sensitivity and reduced POMC projections when exposed perinatally to low-dose BPA, suggesting that these may be antecedents to the metabolic defects observed in BPAexposed mice.
Methods

Animals
All procedures were approved by the Carleton University Animal Care Committee and followed the guidelines of the Canadian Council on Animal Care. Virgin female CD-1 mice were purchased from Charles River and housed in polysulfone cages with ad libitum access to purified AIN93G control diet (Research Diets) and tap water in glass bottles. Two cohorts of dams were used for this study. The first (n = 32) was used for measurements of circulating leptin and leptin sensitivity, and the second (n = 15) was used for the neonatal leptin supplementation study. Animals were maintained on a 12-hour light/dark cycle (lights on at 0800). After mating and confirmation of pregnancy, female mice were single housed and randomly assigned to one of three specially prepared diets (1) AIN93G control diet, (2), AIN93G with 20 mg/kg diet BPA (0.02 ppm BPA), and (3), AIN93G with 4 mg/kg diet diethylstilbestrol (0.004 ppm DES), as described by MacKay et al. (13) . As recommended by vom Saal and Welshons (24), we used DES as a reference estrogen. On day 12 postconception, pregnant mice were injected with 5-bromo-2 0 -deoxyuridine (BrdU; Sigma) in 0.9% saline with NaOH at 160 mg/kg to visualize neurogenesis.
Litters were standardized to 10 pups each when they were 2 days old (P2), with equal sex ratios where possible. Litters of .12 or ,6 at the time of birth were not used in this study, leaving a total of 26 litters for analysis (n = 6, 10, and 9 litters for control, BPA, and DES, respectively). This yielded sample sizes ranging from three to five animals per sex per treatment of early postnatal time points and six to nine per sex per treatment for studying adult leptin sensitivity.
To obtain the most information possible from this study, we used a strategy of sampling pups from litters and replacing them with same-age cross-fosters from our colony. Pups were euthanized at various times for collection of trunk blood, assessment of leptin sensitivity, and histology. At P21, remaining pups were weaned onto the control diet for our studies of adult leptin sensitivity. Cross-fostered pups were not studied in this experiment.
Assessment of leptin sensitivity
At P16, a subset of pups (n = 4 to 5) received an intraperitoneal injection of recombinant mouse leptin (PeproTech catalog no. 450-31) at 3 mg/g and were euthanized 45 minutes later by decapitation. After overnight fixation in 2% paraformaldehyde and cryoprotection in 30% sucrose, brains were sliced (40-mm thick) on a cryostat and processed for phospho-STAT3 (pSTAT3) immunofluorescence using rabbit antipSTAT3 (Tyr705; 1:1000; Cell Signaling Technology, catalog no. 9145; RRID: AB_10140371), as described by Caron et al. (25) . At P130, a cohort of adult animals (n = 6 to 9) were given vehicle (0.9% saline) injections at 1900 for 3 consecutive days to establish a baseline measure of overnight food intake and bodyweight change. On the next 2 nights, animals were given injections of recombinant mouse leptin (2.5 mg/g; PeproTech catalog no. 450-31). Body weight after 2 nights of leptin treatment and average food intake over those 2 nights were compared with the average baseline measures. After a 20-day recovery period, animals were fasted overnight and injected with either vehicle (0.9% saline) or leptin (3.5 mg/g) and euthanized 6 hours later for quantitative reverse transcription polymerase chain reaction (qRT-PCR; n = 3 to 5).
qRT-PCR
Animals were euthanized by decapitation 6 hours after leptin treatment. Brains were rapidly removed and sliced into 1-mm coronal sections using a brain-slicing matrix (Zivic Instruments). Bilateral micropunches containing the ARC were collected and frozen on dry ice and stored at 280°C until RNA extraction. RNA was extracted using TRIzol (Thermo Fisher Scientific) according to the manufacturer's instructions. Complementary DNA synthesis and qRT-PCR were performed as described by MacKay et al. (13) . The 2 2ΔΔCt method was used to calculate the expression of Pomc, AgRP, and Npy relative to the geometric mean of the housekeeping genes Gapdh and b-actin with same-sex saline-treated controls used as baselines. Primer sequences were as follows: Gapdh-F: GCAGTGGCAAAGTGGAGATTGTTGC; Gapdh-R: CCCGTTGATGACAAGCTTCCCATTC; b-actin-F: GAACCCTAAGGCCAACCGTG; b-actin-R: GGTACGACCA-GAGGCATACAG; Pomc-F: GCCCTCCTGCTTCAGACCTC; Pomc-R: CGTTGCCAGGAAACACGG; AgRP-F: CGGAGGT-GCTAGATCCACAGA; AgRP-R: AGGACTCGTGCAGCCT-TACAC; NPY-F: TACCCCTCCAAGCCGGACAA; and NPY-R: TTTCATTTCCCATCACCACATG.
Histology
Brains from pups euthanized at P21 were processed for immunofluorescence as described in MacKay et al. (13) and Ishii and Bouret (26) . Sections were incubated with rabbit anti-POMC precursor (27-38) (1:2500; Phoenix Pharmaceuticals catalog no. H-029-30; RRID: AB_2307442) or POMC and rat anti-BrdU (1:1000; Abcam catalog no. ab6326; RRID: AB_305426; Table 1 ) and were analyzed by confocal microscopy using AlexaFluor secondary antibodies (1:500; Life Technologies). The boundaries of the PVN and ARC were located using 4 0 ,6-diamidino-2-phenylindole counterstaining with coordinates from George and Franklin (27) . POMCimmunopositive fibers were analyzed in ImageJ (National Institutes of Health) by thresholding, binarizing, and skeletonizing Z-stacks collected bilaterally at 1-mm intervals in at least three sections of the PVN (20.70 to 20.94 mm relative to bregma) and the dorsomedial hypothalamus (DMH) in the region 21.58 to 21.82 mm relative to bregma at 310 magnification. This approach converts fibers with a range of staining intensities to single pixel-wide skeletons, reducing the influence of peptide content and staining intensity on the estimation of fiber density. POMC and BrdU colocalization were analyzed using confocal microscopy to collect bilateral Z-stacks at 1-mm intervals at 320 magnification in five serial sections through the rostrocaudal axis of the ARC (21.46 to 22.06 mm relative to bregma). Z-stacks were imported into ImageJ and manually counted by an observer blind to animal identity. The threedimensional nature of the Z-stacks allowed for positive identification of colocalization of POMC and BrdU, which present cytoplasmic and nuclear staining, respectively. One animal was removed from this analysis because of faulty BrDU staining.
Measurement of circulating leptin levels
Serum leptin levels in samples collected from pups euthanized at P2, P8, P10, P12, P16, and P21 were measured in duplicate using mouse leptin enzyme-linked immunosorbent assay kits (Millipore) according to the supplied directions (n = 3 to 4 per sex, treatment, time point; n = 111). The sensitivity of this assay was 0.05 ng/mL. The intra-and interassay coefficients of variation were 7.7% and 3.28%, respectively.
Supplemental leptin treatment
For the study of postnatal leptin supplementation, a new cohort of litters (n = 15) was generated as previously described. From P4 to P10, one male and one female from each litter was given daily subcutaneous injections of either recombinant mouse leptin (5 mg/g; PeproTech catalog no. 450-31) or vehicle (0.9% saline), yielding five pups per sex, treatment, and postnatal injection (n = 60). All pups were euthanized at P21 and processed for histology.
Statistical analysis
No same-sex littermates were included in any analyses. Data were analyzed with SPSS 17 (IBM Corp.). Two-way analysis of variance (ANOVA) with sex and perinatal treatment as factors was used for most analyses where appropriate. Leptin-surge data were analyzed by three-way ANOVA with time, sex, and perinatal treatment as factors. Within-subjects time-course data, such as maternal body weight, adult leptin response, and neonatal body weight during leptin supplementation, were analyzed by repeated-measures ANOVA, with day as the within-subjects factor. In the absence of significant interactions, means of perinatal treatment were compared by main effect contrasts. Significant two-or three-way interactions were further analyzed by simple main effects analysis, or Fisher protected least significant difference test. Statistical significance was defined as P , 0.05. All data are represented as mean 6standard error of the mean.
Results
Maternal and pup characteristics were not altered by BPA exposure Maternal exposures to the test compounds were estimated by measuring daily food intake and body weight. During gestation, dams consumed an average of 2.97 mg/kg/d of BPA and 0.72 mg/kg/d of DES. During the first 14 days of lactation, dams consumed an average of 7.94 mg/kg/d of BPA and 1.56 mg/kg/d of DES (Table 2) . Maternal body weight and food intake were not affected by BPA or DES [P . 0.05; Fig. 1(a) and 1(b) ], 
BPA-exposed animals exhibited programmed leptin insensitivity
To test whether BPA exposure affects the central response to leptin during the suckling period, we injected male and female pups with 3 mg/g leptin and measured pSTAT3-immunopositive nuclei in the hypothalamus 45 minutes postinjection. Our analysis did not reveal any effects of sex (F 1,21 = 0.82; P = 0.376) or perinatal treatment in the ARC [F 2,21 = 0.279; P = 0.76; Fig. 2(a) ].
We next raised a group of mice to adulthood (P130) and assessed their response to leptin by measuring food intake and body weight over two consecutive nights of leptin treatment. Although there was a significant main effect of sex in body weight [F 1,42 = 28.350; P , 0.001; Fig. 2(b) ], similar to our previous findings of BPA-exposed adults on a control diet (13) , there was no effect of perinatal treatment on body weight. Overnight leptin treatment reduced average overnight food intake from baseline, but the extent of this reduction did not differ between the treatment groups [ Fig. 2(d) ]. Repeated-measures ANOVA of the bodyweight response to leptin treatment revealed a significant main effect of time (F 1.972,82.808 = 33.752; P , 0.001 by Huynh-Feldt correction « = 0.986) and a significant interaction between time and perinatal treatment (F 3.943,82.808 = 5.229; P = 0.007 by Huynh-Feldt correction « = 0.986). Post hoc testing indicated that by the second day of leptin treatment, control mice lost significantly more body weight than either BPA-or DES-treated mice [P = 0.004 and P = 0.034, respectively; Fig. 2(e) ].
After a 20-day recovery period, we next examined leptin-induced gene expression in the ARC in the same mice. We found significant main effects of perinatal treatment of Pomc (F 2,34 = 5.290; P = 0.01) and injection (F 1,34 = 8.995; P = 0.005), as well as a significant interaction between injection and perinatal treatment (F 2,34 = 6.996; P = 0.003). Pairwise comparisons between the leptin-and saline-injected mice demonstrated a significant upregulation of Pomc mRNA in control mice only [P , 0.001; Fig. 2(f) ]. We did not find any significant effects of sex, treatment, or injection on AgRP or Npy (Fig. 2(g) and 2(h) ].
BPA exposure led to reduced hypothalamic POMC projections
Having shown evidence of reduced leptin sensitivity in adulthood, we decided to study whether BPA could affect the structural development of the melanocortin circuitry. In mouse pups euthanized at P21, we found a significant main effect of sex (F 1,17 = 9.027; P = 0.008), as well as a significant main effect of perinatal treatment [F 2,17 = 4.402; P = 0.029; Fig. 3(a) ] on POMC immunofluorescence in the PVN. There was no interaction between sex and maternal treatment. Main-effect contrasts indicated that BPA-treated mice had significantly reduced POMC immunofluorescent fiber density compared with control mice, and that females had greater POMC fiber density than males [P = 0.01; Fig. 3(a) ]. In the DMH, we found a similar pattern of reduced POMC staining among females, but neither the main effects of maternal treatment (F 2,17 = 0.805; P = 0.463) or sex (F 1,17 = 0.001; P = 0.982) nor their interaction (F 2,17 = 1.736; P = 0.206) was statistically significant (Supplemental Fig. 1 ).
We next asked whether an altered pattern of neurogenesis could account for our results. Because most leptin-sensitive hypothalamic neurons are born on E12 in mice (26), we analyzed P21 mice exposed to BrdU via maternal injection at E12. There was no difference in the number of POMC-immunopositive neurons between any of the treatment groups (F 2,16 = 0.662; P = 0.529), or between males and females [F 1,16 = 1.386; P = 0.256; Fig. 3(c) ]. We also observed no effect of either sex (F 1,16 = 0.469; P = 0.503) or perinatal treatment (F 2,16 = 1.103; P = 0.356) on the number of BrdU-immunopositive nuclei in the ARC. There was also no effect of sex 
Delayed leptin surge in BPA-exposed animals
Because the surge in circulating leptin during the postnatal period is believed to play an important role in the development of projections from the ARC, we studied serum leptin levels in pups euthanized at P2, P8, P10, P12, P16, and P21. In agreement with previous reports (28), we did not find a main effect of sex on leptin concentrations during the postnatal period (F 1,75 = 0.19; P = 0.664), nor did we find an interaction between sex and perinatal treatment (F 2,75 = 0.807; P = 0.45). However, we did find significant main effects of perinatal treatment (F 2,75 = 4.054; P = 0.021) and time (F 5,75 = 7.629; P , 0.001), as well as a significant interaction between perinatal treatment and time (F 10,75 = 3.850; P , 0.001). To further scrutinize this interaction, we examined the simple main effect of perinatal treatment as a function of time and found this to be significant at P8 (F 2,75 = 9.673; P , 0.001), P10 (F 2,75 = 4.381; P = 0.016), and P12 (F 2,75 = 6.188; P = 0.003). Contrast analysis at each of these time points indicated that control mice had significantly higher circulating leptin than either BPA-or DES-treated mice at P8 (P = 0.002 and P = 0.001, respectively), and that BPA-treated mice had significantly higher circulating leptin level than control or DES-treated mice at P10 (P = 0.037 and P = 0.003, respectively) and P12 (P = 0.044 and P = 0.02, respectively). Together, these data indicate that the leptin surge, centered on P8 in control animals, is delayed in BPA-treated animals, and absent altogether in DES-treated animals [ Fig. 4(a) and 4(b) ].
Supplemental leptin rescued POMC projections in female animals exposed to BPA To test whether our observation of reduced POMC projections into the PVN in BPA-exposed animals could be attributed to an altered pattern of postnatal leptin secretion, we studied the same pathway in mice that had been given supplemental leptin during the surge period. Leptin did not affect body weight relative to saline treatment in either sex at any point during postnatal treatment [three-way interaction between postnatal day, sex, and group; F 3.679,44.146 = 0.569; P = 0.673 by Greenhouse-Geisser correction « = 0.218; Fig. 5(a) and 5(b) ]. Analysis of POMC-immunopositive fiber density in saline-treated mice replicated our previous finding of reduced density in BPA-exposed mice (F 2,24 = 3.589, P = 0.043 for main effect of perinatal treatment; P = 0.013 for post hoc test; Fig. 5(c) ]. When we added data from leptintreated animals to the model, we found a significant main effect of sex (F 1,48 = 13.508; P = 0.001) and an interaction between sex and injection (F 1,48 = 6.582; P = 0.013), showing that females had a much stronger response to the leptin treatment than males. Post hoc analysis of this result showed that this difference was driven by the effect of 
Discussion
In our previous study of BPA exposure, we found that mice exposed to a higher dose of BPA (0.02 ppm in the maternal diet) exhibited sex-specific metabolic impairments in adulthood, with females being prone to dietinduced obesity and males to impaired glucose tolerance (13) . Our observations in the melanocortin circuitry of these animals led us to suspect these programming effects were mediated by reduced leptin sensitivity. Male BPAexposed mice exhibited reduced POMC-immunopositive projections into the PVN, and females had reduced Pomc expression despite hyperleptinemia (13) . Because our earlier study was carried out in adult animals who had already begun to exhibit a metabolic phenotype, we could not determine if these factors were causal in the phenotype. In the current study, we focused on neonates and young adult mice that had not yet begun to show a phenotype, and we demonstrated that reduced POMCimmunopositive fiber density and central leptin insensitivity existed in these animals, as well, suggesting altered development of the central melanocortin system is involved in the BPA-induced metabolic phenotype that eventually develops.
Because BPA is a xenoestrogen, we elected to use DES as a reference estrogen, continuing with a dose used in our previous study, and originally established by Ryan et al. (16) . Studies using DES in this way tend to use doses 10 to 100 times lower than the BPA dose (24) , though the complexities of in vivo systems mean that different ratios may better suit different outcomes, dosing regimens, and experimental models. Because the outcomes measured in our study have never been studied before, to our knowledge, in the context of DES, few a priori assumptions could be made regarding its expected outcomes. Because of this, we chose to treat it as a reference estrogen rather than as a strict positive control. This approach allows inferences to be made from concordances and discordances between the two compounds, suggesting areas of our phenotype that depend on BPA's nonestrogenic activities. It is important to bear in mind, however, that these may also be due to the dose of DES we chose and its relative potency.
In our previous study, we found BPA-exposed mice did not exhibit a body-weight phenotype when consuming AIN93G, our standard control diet for these experiments, and only began to exhibit body-weight differences when placed on a high-fat diet (13) . Of course, differences in neurobiology in BPA-exposed, diet-induced obese animals may be due to either the BPA or the obesity, and thus the design of our previous experiment could show that a particular vulnerability existed in these animals but could not show that this vulnerability was evident before the onset of diet-induced obesity. In the current study, we found evidence of reduced adult leptin sensitivity in BPAand DES-exposed adult mice raised under conditions similar to our last study but maintained on the control diet into adulthood. This occurred without any group differences in food intake, raising the possibility that BPA and DES treatments selectively affect the metabolic response to leptin. These results show that subtle deficits in leptin sensitivity exist even in animals not on a high-fat diet. Estrogens tend to be anorectic in the context of acute adult exposure, but their organizational effects during development promote obesity. Indeed, our observations were very similar to those noted in mice exposed neonatally to 17b-estradiol, a treatment that yields a form of leptin resistance that, like ours, depends on disturbances in Pomc regulation but not pSTAT3 signaling (23) . This, and the fact that both BPA and DES produced similar results in our current study, suggests that reduced adult leptin sensitivity is an estrogenic effect. Importantly, the molecular underpinnings of this phenomenon remain unclear; for example, it is not certain that the lack of deficits we observed in leptin-induced pSTAT3 at P16 predicts the same effect in adulthood. However, the transcriptional deficit we observed represents a critical link between leptin-receptor stimulation and the physiological response, and is consistent with our previous findings (13) . Notably, our choice of the AIN93G diet has the advantage of being phytoestrogen free, a critical consideration in studies of endocrine disruption, but its low-phytoestrogen, high-casein formula has metabolic effects of its own compared with standard laboratory chow (29, 30) , though these would at least be consistent across all groups.
Both BPA-and DES-exposed mice exhibited a disrupted leptin surge. Studies of maternal food restriction (21) and obesity (22) found associations between such disruptions and long-term functional and structural changes in the melanocortin circuitry. Moreover, neonatal leptin supplementation is protective against future obesity in models of obesogenic developmental programming (31, 32) . Importantly, our model did not completely abrogate postnatal leptin secretion and some features under its control may continue to develop normally with only basal levels of leptin secretion.
Our finding that BPA-exposed mice exhibited reduced density of the POMC-immunopositive fibers in the PVN was notable because we had previously observed this in adult, male BPA-exposed mice (13) , and numerous other studies using different models of developmental programming have shown similar results, as well (21, 33) . This effect appears to be region specific, as we did not find matching results in the DMH. We interpreted these immunofluorescent data to indicate disrupted axonal growth; however, it is important to note that transient effects like reduced POMC expression, transport, or turnover could be other potential interpretations of these data, as well. Indeed, these other interpretations are especially important when considering our previously published results in adult animals, where transient effects specific to adults such as the estrous cycle, feeding status, and postweaning environment may explain why adult females did not show the same deficits in POMC staining. In the current study, we found that supplemental leptin was only able to rescue melanocortin innervation in female animals, although BPA induced a deficient leptin surge in both sexes. This is consistent with previous reports showing stronger ameliorative effects of supplemental leptin in females (31, 32) . The origin of these sex differences is not known, but the discord we observed between BPA and DES may be instructive. Given that DES treatment also disrupted the leptin surge but, unlike BPA, did not produce alterations in POMC projections to the PVN, perhaps this is due to a cell-autonomous effect of BPA on developing POMC neurons. This would likely depend on a receptor targeted by BPA but not DES, and also one for which a role in sexual differentiation is known. The androgen receptor is one such candidate because BPA can act upon it as an antagonist (34), although zebrafish studies show that BPA can also behave agonistically (7, 8) . However, additional research will be required before the importance of BPA's nonestrogenic effects in our model and others can be known with any certainty. It is important to bear in mind that although previous studies have linked the development of these projection pathways to adult metabolic homeostasis (20, 35) , further research will be needed evaluate the functional outcomes of our rescue paradigm in adult animals.
Despite movement toward alternative compounds, BPA-based plastic remains ubiquitous, and exposure to BPA borders on unavoidable (2) . We based our choice of dose on previous studies of oral exposure to BPA in pregnant and lactating rodent models, with the aim of Figure 5 . Supplemental leptin rescued POMC projections in female mice exposed to BPA. (a, b) Leptin treatment during the neonatal period did not affect body weight in either male or female pups. (c) BPA-exposed animals had a reduced density of POMC projections in the PVN, and this was rescued in females by the application of exogenous leptin from P2 to P10. Example images captured at 310 magnification. Scale bars = 250 mm. Data were recorded in arbitrary units (AU) and shown as mean 6 standard error of the mean. * P , 0.05 BPA vs control animals; ** P , 0.01 saline vs leptin in BPA females; † † † P , 0.001 vs males; ns indicated in bar labels.
producing environmentally relevant exposure levels in the offspring. Our dams consumed an average of 2.97 mg/kg/d BPA during gestation and 7.94 mg/kg/d during early lactation (14) . We found that during gestation, a 5-mg/kg/d maternal oral dose of BPA produces in E17 to E18 fetuses an average serum concentration of 2 pg/mL, and this figure is lower than the median 2.3 ng/mL concentration detected in human fetuses (36) . Similarly, 100 mg/kg oral doses of BPA yield estimated doses of approximately 0.32 mg/kg in P6 to P10 Sprague-Dawley pups (37), a value within the range of reported concentrations in human breast milk (38) .
In summary, we have shown that perinatal exposure to BPA produces in the rodent brain a series of structural and functional neurobiological alterations that could predispose to the metabolic disturbances seen in adult BPA-exposed animals (13). Our observations of altered postnatal leptin secretion and melanocortin system development in mice lead us to suggest that the main period of vulnerability for mice is in the early postnatal period. This parallels other mouse models of developmental programming, such as maternal obesity (22), food restriction (21) , and diabetes (33) , and suggests that programming induced by endocrine-disrupting compounds may share with them a common etiology in the hypothalamic feeding circuitry.
